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A Novel Population of Human Melanoma-Specific CD8 T Cells
Recognizes Melan-AMART-1 Immunodominant Nonapeptide but
Not the Corresponding Decapeptide1
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HLA-A2-restricted cytolytic T cells specific for the immunodominant human tumor Ag Melan-AMART-1 can kill most HLA-
matched melanoma cells, through recognition of two naturally occurring antigenic variants, i.e., Melan-A nonamer AAGIGILTV
and decamer EAAGIGILTV peptides. Several previous studies have suggested a high degree of TCR cross-reactivity to the two
peptides. In this study, we describe for the first time that some T cell clones are exclusively nonamer specific, because they are not
labeled by A2/decamer-tetramers and do not recognize the decamer when presented endogenously. Functional assays with pep-
tides gave misleading results, possibly because decamers were cleaved by exopeptidases. Interestingly, nonapeptide-specific T cell
clones were rarely V2.1 positive (only 1 of 19 clones), in contrast to the known strong bias for V2.1-positive TCRs found in
decamer-specific clones (59 of 69 clones). Molecular modeling revealed that nonapeptide-specific TCRs formed unfavorable in-
teractions with the decapeptide, whereas decapeptide-specific TCRs productively created a hydrogen bond between CDR1 and
glutamic acid (E) of the decapeptide. Ex vivo analysis of T cells from melanoma metastases demonstrated that both nonamer and
decamer-specific T cells were enriched to substantial frequencies in vivo, and representative clones showed efficient tumor cell
recognition and killing. We conclude that the two peptides should be regarded as distinct epitopes when analyzing tumor immunity
and developing immunotherapy against melanoma. The Journal of Immunology, 2007, 179: 7635–7645.
M elan-AMART-1 is a tumor differentiation Ag which isexpressed by melanocytes and malignant melanomacells from tumors of 95% of patients. Melan-A-spe-
cific CD8 T cells are readily detectable in the majority of HLA-
A*0201pos normal individuals and in melanoma patients. During
melanoma progression, Melan-A-specific CD8 T cells become ac-
tivated and accumulate in metastatic lesions (1–3). Two natural
peptide variants derived from Melan-A are presented by HLA-
A*0201 and recognized by Melan-A-specific T cells: the nonapep-
tide AAGIGILTV (AA), and the decapeptide EAAGIGILTV
(EAA), differing in glutamic acid (E) at peptide position one. Both
peptides are naturally processed and presented by melanoma cells.
The nonamer has been directly isolated from a melanoma cell line
by acid elution (4). Evidence for decamer presentation by HLA-
A*0201 is indirect and incomplete, essentially based on efficient
recognition by CD8 T cell clones with preference for the decamer
(5–7). Conclusive evidence exists for presentation of the same de-
capeptide by HLA-B*3501, where T cell clones derived from mel-
anoma metastases exclusively recognize the decamer but not the
nonamer (8).
Efficiency of recognition of human tumor cells by CTLs is often
suboptimal, in part explaining lack of immune protection from
tumor progression. For a full characterization of HLA-A*0201/
Melan-A-specific T cells, further studies are necessary, e.g., to
determine whether the nonapeptide and decapeptide are differen-
tially expressed by melanoma cells and professional APCs, and to
elucidate whether T cell recognition of the two peptides occurs
differently, and by distinct T cells.
Several studies suggest that the majority of Melan-A-specific T
cells preferentially recognize the decamer rather than the nonamer
(5–7, 9). A large number of T cell clones generated from HLA-
A*0201pos healthy donors and patients demonstrated dominance of
decamer-specific T cells, whereas T cells with preferred recogni-
tion of the nonapeptide were rare. Decamer vs nonamer specificity
was usually determined by 51Cr-release assays using target cells
loaded with synthetic peptides. In most cases, the T cells were
cross-reactive against both peptides, whereby the decapeptide was
more efficiently recognized than the nonapeptide. Synthetic pep-
tides, however, bear the problem that they may include contami-
nating peptides with other sequences, and that they can be de-
graded by peptidases during bioassays. Current peptide synthesis
and separation techniques cannot prevent the presence of minute
amounts of deletion peptides, which may elicit in vitro and in vivo
T cell responses, owing to the high sensitivity of T cells.
In the present study, we determined the specificity of selected
A*0201/Melan-A-specific T cell clones and of T cell populations
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from melanoma patients analyzed ex vivo. We used peptides with
the two natural sequences and modified peptides designed for de-
fined positioning in the A*0201 peptide-binding pocket. The re-
sults show that T cells can efficiently distinguish between Melan-A
nonamer and decamer, revealing the existence of two distinct




The melanoma cell lines Me 275 and Me 290 (HLA-A2pos/Melan-Apos),
and NA8-MEL (HLA-A2pos/Melan-Aneg) were maintained in RPMI 1640
(Invitrogen Life Technologies) supplemented with 10% FCS, nonessential
amino acids, and penicillin-streptomycin. Blood was withdrawn from
healthy donors or stage III/IV melanoma patients, who also provided tumor
infiltrating lymphocyte (TIL)3/tumor-infiltrated lymph node cells (TILNs)
obtained through surgery. Patients had not received chemotherapy, immu-
notherapy, or irradiation. Ficoll-Paque-centrifuged PBMC were cryopre-
served in RPMI 1640, 40% FCS, and 10% DMSO. Melan-A-specific T cell
clones M77–80 and A42 were established by limiting dilution from TIL
and mixed lymphocyte tumor cell cultures, respectively (10, 11). Clones
LAU 337–6B7 and BC25-R3 were purified from patient PBL by ex vivo
cell sorting (12) and from healthy donor PBMC stimulated by Melan-
A26–35 (A27L) peptides, respectively.
Stimulation of CD8 T cells was done with freshly isolated HLA-
A*0201pos PBMCs and cultivated at 0.2  106 cells/well (96 U-bottom
plates) in the presence of 10 M Melan-A peptides. IL-2 was added at day
2 at 1000 IU/ml. Media was changed every other day and CD8 T cells
evaluated at day 10.
Peptides
Melan-A peptides used are listed in Table I. They were synthesized by
standard solid-phase chemistry on a multiple peptide synthesizer (Applied
Biosystems) by using F-moc for transient N-terminal protection. Peptides
were analyzed by mass spectrometry. The homogeneity of all peptides was
90%, as indicated by analytical HPLC (13). In functional assays, influ-
enza matrix protein-derived peptide (GILGFVFTL) was used as negative
control.
Fluorescent reagents and flow cytometry
HLA-A*0201/peptide tetrameric complexes were produced as described
(2). V2-specific purified mAb was purchased from Beckman Coulter
(clone RA8.4). All other Abs were purchased from BD Pharmingen. Sam-
ples were analyzed on a FACSCan or CANTO (BD Biosciences).
Tetramer-guided cell sorting and cloning at limiting dilution
conditions
TIL, TILN, and stimulated PBMC were labeled with peptide-MHC (p-
MHC) tetramers bearing two different fluorochromes. Briefly, CD8pos T
cells were positively enriched using anti-CD8-coated magnetic microbeads
(Miltenyi Biotec), and washed in PBS 0.2% BSA, 5 mM EDTA (FACS
buffer). Cells were incubated for 30 min at 4°C in FACS buffer with al-
lophycocyanin-conjugated tetramers, then, after washing, with PE-conju-
gated tetramers, and finally, with FITC-conjugated CD8-specific mAb.
Cells were immediately sorted with a FACSVantage cell sorter, and cocul-
tured in limiting dilution conditions with 104 irradiated allogenic PBMC,
150 IU/ml rIL-2, and 1 g/ml PHA-leukoagglutinin (PHA-L). Proliferating
wells were screened at days 7–9. Subsequently, they were periodically
restimulated with PHA, irradiated feeder cells and rIL-2. CD8 T cell clones
were evaluated with tetramers for TCR specificity and subsequently ana-
lyzed as described in Results.
Assessment of Ag recognition by Melan-A-specific CD8 T cell
clones
Ag-specific cytotoxicity was assessed using chromium-release assays. Tar-
get cells were labeled with 51Cr for 1 h at 37°C and washed three times.
Labeled target cells (1000 cells in 50 ml) were added to varying numbers
of effector cells in V-bottom microwells. Where indicated, NA8-MEL cells
labeled with 51Cr were infected with recombinant vaccinia virus coding for
Melan-A minigenes at a multiplicity of infection of 10, for 2 h before
adding Melan-A-specific CD8 T cells at different L-T ratios. In peptide
titration experiments, T2 target cells were incubated in presence of titrated
peptide for 15 min at room temperature, before the addition of effector T
cells. Chromium release was measured in supernatant after 4 h of incuba-
tion at 37°C. The percentage of specific lysis was calculated as following:
100  ((experimental  spontaneous release)/(total  spontaneous
release)).
Modeling the TCR-p-MHC complex
Homology models of the variable domain of the TCR bound to the de-
capeptide ELAGIGILTV presented by HLA-A*0201 were built using
Modeller 6v2 (14), based on crystal structures of TCR and HLA-A2 MHC
from the Protein Data Bank (www.rcsb.org/). From the available structures
of TCR or TCR-p-MHC class I complexes, we selected the variable do-
mains of nine TCR (V and V) as templates for the homology modeling:
1fo0, 1g6r, 1kb5, 1kj2, 1lp9, 1mi5, 1nfd, 1oga, 2ckb. Lower resolution
redundant structures were excluded. In addition, three unbound TCRV
(1b88, 1i9e, 1h5b) and two unbound TCRV (1bec, 1ktk) structures were
added to the templates list. The TCRV structure 1934.4 was also used
(15). The three last templates structures were 1ao7 and 1bd2, as TCR
bound to HLA-A2, and 1jf1, the structure of the ELAGIGILTV peptide
presented by HLA-A*0201.
Once a homology model was obtained, each CDR loop was refined
while the rest of the complex including the other CDR loops remained
unchanged. The algorithm for the loop modeling consists in a cycle of
molecular dynamics, combined with simulated annealing, optimizing the
Modeller pseudo energy function. When possible, this function was im-
proved by adding restraints specific to the nature of the CDR loop. These
restraints were derived from the rules given by Al-Lazikani et al. (16): the
identification of key amino acids defines limitations to the conformation
space accessible to a CDR loop.
Binding free energy calculations
To estimate the role of the CDR1 residues on the TCR association to
p-MHC, we used a binding free energy estimation and decomposition
scheme using the molecular mechanics-generalized born surface area ap-
proach (17). We used previously this method on a TCR-p-MHC system and
successfully reproduced the results of an experimental alanine scanning
(18). The binding free energy was estimated according to the following
equation: Gbind  EvdW  Eelec  Eintra  Gelec,desolv  Gnp,desolv 
TS (1), where EvdW and Eelec are the van der Waals and electrostatic
interaction energies between the TCR and the p-MHC. Eintra is the vari-
ation of the internal energy of both partners upon complexation. Because
we performed the calculations on a single model, we have Eintra  0.
Gelec,desolv and Gnp,desolv are the electrostatic and nonpolar desolvation
energies upon complexation, respectively. Gelec,desolv is calculated ac-
cording to the GB-MV2 generalized Born model (19, 20). Gnp,desolv is
assumed to be proportional to the solvent accessible surface area that is
buried upon complexation. We neglected the entropy term TS.
The use of equation (1) allows a straightforward decomposition of the
binding free energy into backbone and side chain contributions for each
residue. A detailed description of the approach can be found in Ref. 18. The
binding free energy contributions have been calculated for all residues. All
calculations were performed using the CHARMM package (version c31b1)
(21) and the CHARMM22 all-atoms force field (22).
3 Abbreviations used in this paper: TIL, tumor infiltrating lymphocyte; TILN, tumor-
infiltrated lymph node cell; p-MHC, peptide-MHC.
Table I. Natural and modified Melan-A peptides used in this study
Peptide Abbreviation Sequencea
Nonamer MelanA27–35 AA AAGIGILTV
MelanA27–35(A28L) AL ALGIGILTV
MelanA27–35(A27L) LA LAGIGILTV
Decamer MelanA26–35 EAA EAAGIGILTV
MelanA26–35(A27L) ELA ELAGIGILTV
MelanA26–35(E26A) AAA AAAGIGILTV
MelanA26–35(E26A, A27L) ALA ALAGIGILTV
a Modifications are indicated in bold letters.
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Results
A subset of Melan-A-specific CD8 T cell clones fail to bind to
Melan-A tetramers
Previous studies have shown that the vast majority of Melan-A-
specific CD8 T cell clones recognize the decapeptide EAA-
GIGILTV more efficiently than the nonamer AAGIGILTV (Table
I), as determined by cytotoxicity assays using target cells labeled
with titrated peptide doses (5, 6). In the following we will refer to
these clones as “majority” clones. However, there are a few ex-
ceptional clones with superior recognition of nonapeptide, but they
also seem to recognize synthetic decapeptide. In the following we
will refer to the latter as “minority” clones, because they appear
less frequent, despite that they have been actually described earlier
(10, 23) than the majority clones (24). Based on current knowl-
edge, it is believed that the two peptides represent two variants of
the same HLA-A2-restricted epitope. To challenge this view, we
first tested the ability of representative clones to bind to A2/
Melan-A tetramers constructed with the parental decapeptide
Melan-A26–35 (tEAA), the parental nonapeptide Melan-A27–35
(tAA), or the Melan-A26–35(A27L) decapeptide analog (tELA; Ta-
ble I). We used several T cell clones displaying different recogni-
tion pattern of Melan-A peptides, i.e., the majority clones
BC25-R3 and LAU 337–6B7 preferentially reacting to the natural
decapeptide (EAA), and the minority clones A42 and M77–80
preferentially recognizing the natural nonapeptide (AA) (5, 9). As
shown in Fig. 1A, the tetramer tAA successfully labeled A42 and
M77–80 clones, while tetramers tEAA and tELA surprisingly did
not stain these minority clones. As expected, (Fig. 1A), majority
clones were efficiently stained by Melan-A tetramers tELA and
tEAA. The clone BC25-R3 displayed a low tAA staining. This is
FIGURE 1. Tetramer labeling of
minority and majority Melan-A-spe-
cific T cell clones. T cell clones were
stained with anti-CD8-FITC and PE-la-
beled A2/Melan-A tetramers (t) pre-
pared with various peptides (Table I),
i.e., either ELA, EAA, AA (A, upper
panels) or AL, AAA, ALA, LA (B,
lower panels).
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likely due to its weak avidity, supported by the relatively high
peptide concentrations required for target cell recognition (Fig. 2A
and Table II), and the fact that this clone was derived from a
healthy donor of whom it is known that they frequently give rise
to low avidity clones (25). Differential binding to tetramers tEAA
vs tAA suggested that the glutamic acid (E) at the first position of
the peptide prevented binding of the tEAA tetramer to minority
clones. To explore this possibility, we generated tetramers loaded
with a series of modified peptides (Table I). Although the tetramer
prepared with the modified nonamer tAL (ALGIGILTV) was rec-
ognized neither by majority nor by minority clones, all the three
other tetramers tAAA (AAAGIGILTV), tALA (ALAGIGILTV)
and tLA (LAGIGILTV) labeled the Melan-A-specific clones effi-
ciently (Fig. 1B), showing that the minority clones are able to
recognize various Melan-A modified decapeptides without glu-
tamic acid in position one. The data thus suggest that glutamic acid
at the N terminus may hinder recognition by the minority clones.
Assessment of peptide and melanoma cell recognition by
minority clones
To determine structure-function relationships, the relative antigenic
activity of various peptide variants (Table I) was quantified by cytox-
icity assays with titrated amounts of peptides (Fig. 2A). As shown in
previous studies (5–7, 10), majority Melan-A-specific clones dis-
played the usual pattern of recognition hierarchy because parental and
modified immunodominant decamers EAA and ELA were better rec-
ognized than the natural nonapeptide AA (Fig. 2A and Table II). To-
gether with data shown in Fig. 1, these findings confirmed that the two
majority clones bore the usual fine specificity that is frequently ob-
served in HLA-A2/Melan-AMART-1-specific human T cell clones (5,
7). The highest functional avidity (recognition at lowest peptide con-
centrations) was observed to ELA and EAA peptides by the majority
clones LAU 337 6B7 and BC25-R3, even if the latter clone showed
FIGURE 2. Ag recognition by T cell clones assessed in cytotoxicity assays. A, The relative antigenic activities of natural and modified Melan-A peptides
were determined in cytotoxicity assays with T2 target cells (E:T ratio 10:1) in presence of increasing peptide concentrations. B, Tumor cell lysis was
assessed using Me 275 and Me 290 melanoma cell lines (HLA-A*0201pos/Melan-Apos). C, Lysis of NA8-MEL cells infected with recombinant vaccinia
viruses coding for ELA, EAA, or AA. Similar results were obtained in two independent experiments.
Table II. Recognition of Melan-A natural and modified peptides
EC50 of T Cell Clonesa
Peptide A42 M77–80 LAU 337 6B7 BC25-R3
ELA (ELAGIGILTV) 3.1 3.2 0.021 0.044
EAA (EAAGIGILTV) 262.5 331.8 0.06 2.5
AA (AAGIGILTV) 10.4 99.6 6.2 61.1
aEC50 values correspond to peptide concentrations (nanomoles) required to obtain
50% of maximal lysis of peptide-loaded target cells.
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lower avidity to most peptides (Fig. 2A and Table II). Interestingly,
despite that the two minority clones A42 and M77–80 were not
stained by the corresponding tetramers, they nevertheless recognized
target cells loaded with EAA and ELA decapeptides, albeit at much
lower avidities than the majority clones (Fig. 2A and Table II). Fur-
thermore, none of the clones recognized the modified nonamer AL
(Fig. 2A). In contrast, AAA, ALA, and LA peptides were recognized
by both types of clones, confirming tetramer binding results (Fig. 1B).
The latter two peptides were particularly well recognized by minority
clones.
Next, we tested the ability of the clones for specific recognition
and killing of melanoma cells. The two Melan-Apos cell lines Me
275 and Me 290 were efficiently lysed by both minority clones and
majority clones (Fig. 2B), while Melan-Aneg melanoma cells were
not lysed (data not shown). The data confirm that all four clones
expressed TCRs capable to recognize and kill melanoma cells nat-
urally processing and presenting A2/Melan-A epitopes.
Reactivity of minority Melan-A-specific T cell clones correlates
with absence of glutamic acid (E) at the first position of the
peptide
The above data revealed that majority and minority clones showed
preference for deca- and nonapeptides, respectively. However, we
were left with the paradox that minority clones also killed target
cells loaded with EAA and ELA decamers whereas they were not
labeled by the corresponding tetramers. It has been shown that
Melan-A peptides are rapidly degraded in human serum by amino-
and dipeptidyl-peptidases (26, 27). Because we used FCS in our
assays, peptides may have been cleaved during our experiments,
leading to the generation of nonamers in culture wells assessing
decamer reactivity. This would explain the recognition of the nat-
ural and modified decamers by minority clones that we observed in
killer assays (Fig. 2A). First, we performed cytotoxicity assays in
serum free medium, but still obtained some recognition of decam-
ers (data not shown). Alternative explanations are that peptides
may have been cleaved by membrane proteases, or that the de-
capeptides synthesis contained trace amounts of nonapeptides that
coeluted during HPLC separation (data not shown). Therefore, we
designed an approach whereby Melan-A Ags are synthesized, pro-
cessed and presented physiologically by target cells, and therefore
should not be exposed to exopeptidases other than those involved
in natural Ag processing. We prepared recombinant vaccinia vi-
ruses with minigenes coding for AA, EAA and ELA peptides (28,
29), and used them to infect NA8-MEL target cells. As expected,
target cells infected with vaccinia virus-expressing antigenic non-
apeptide were efficiently lysed by the clones, except for the
FIGURE 3. Structural differences
between nona- vs decamer-specific
clones. A, V2.1 expression by minor-
ity and majority clones. Melan-A spe-
cific clones were stained with anti-
V2.1 mAb followed by FITC-labeled
goat anti-rat IgG Ab (bold line) or with
FITC-labeled conjugate alone (filled
histogram). B, Structural modeling of
nonamer vs decamer-specific TCRs
bound to ELA/HLA-A*0201. Compar-
ison of the predicted structure of ELA/
HLA-A2 complex and TCRs V
CDR1 loop from decamer-specific
clones (upper panels) and from
nonamer-specific clones (lower pan-
els). HLA-A2 structures are shown in
blue ribbon, the side chains of TCRs
V CDR1 loop in ball and stick repre-
sentation, and the side chains of the
glutamic acid (Glu374) from ELA pep-
tide in blue stick. Hydrogen bonds are
represented by green dotted lines and
the distance between TCR V2.1
Ser412 and peptide Glu374 is given in Å.
Shortest distances between the CDR1
of nonamer specific clones and peptide
Glu374 are represented by black dotted
lines.
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BC25-R3 clone due to its weak avidity and to the low affinity of
AA peptide to HLA-A*0201 molecules In contrast, target cells
expressing decamers EAA or ELA were only killed by “majority”
clones (Fig. 2C). The results indicate that majority Melan-A-spe-
cific clones indeed failed to recognize Melan-A natural and mod-
ified decamers due to the presence of glutamic acid at the N ter-
minus of the peptide. Therefore, minority clones are exclusively
specific for the nonapeptide, rather than cross-reactive to nona- and
decapeptide. Thus, minority clones can be called nonamer specific,
and majority clones decamer specific.
Structural differences between nonamer- and decamer-specific T
cell clones
Structural properties of peptides and T cell receptors are likely
responsible for this differential recognition. TCR V usage ap-
pears to be diverse, because many different V elements are found
in Melan-A-specific clones (30, 31) such as the ones used above
(data not shown). In contrast, V usage is more restricted in
Melan-A-specific T cells. Indeed, a strong preference for V2.1
usage was found in the preimmune repertoire of circulating Melan-
A-specific CD8 T cells as well as at early stages of T cell devel-
opment (30, 32–34). We analyzed the expression of V2.1 by
Melan-A-specific clones, and found that V2.1 was expressed by
decamer-specific clones, but not nonamer-specific clones (Fig.
3A), suggesting a beneficial role for V2.1 for binding to the
decamer but not the nonamer.
To better understand, the interactions between V portions and
the glutamic acid in Melan-A decapeptides, we performed in silico
modeling of the TCR-p-MHC structure and the decomposition of
the binding free energy calculated with the MM-GBSA approach
(17), for two V2.1pos decamer-specific clones (TCR from clones
LAU 337–6B7 and ELGTASY (35)) and for two V2.1neg
Table III. MM-GBSA contributions of CDR1 side chains (sc)a
Escvdw Escelec  Gscelec,desolv  Gscnp,desolv  Gscbind Escvdw Escelec  Gscelec,desolv  Gscnp,desolv  Gscbind
ELGTASY LAU 337–6B7
Tyr407 0.06 0.01 0.02 0.00 0.03 Tyr407 0.05 0.06 0.02 0.00 0.13
Ser408 0.07 2.10 2.05 0.03 0.15 Ser408 0.06 1.72 1.52 0.00 0.14
Asp409 0.46 60.21 59.10 0.01 0.64 Asp409 0.15 51.91 49.16 0.00 2.60
Arg410 1.13 108.06 108.92 1.03 1.29 Arg410 1.61 75.96 73.40 0.81 4.98
Gly411 0.00 0.00 0.00 0.00 0.00 Gly411 0.00 0.00 0.00 0.00 0.00
Ser412 0.27 2.20 0.91 0.46 3.84 Ser412 0.35 2.09 1.77 0.43 3.94
Gln413 0.35 0.71 0.89 0.02 0.55 Gln413 0.35 4.44 4.46 0.00 0.33
Ser414 0.23 0.27 0.11 0.02 0.64 Ser414 0.24 0.64 1.00 0.06 0.07
Phe415 0.15 0.47 0.51 0.00 0.11 Phe415 0.13 0.38 0.50 0.00 0.01
M77–80 A42
Tyr407 0.11 1.22 1.06 0.00 0.27 Tyr407 0.12 1.38 1.18 0.00 0.31
Thr408 0.05 0.42 0.50 0.00 0.03 Thr408 0.04 1.07 1.31 0.00 0.28
Asn409 0.41 0.59 0.15 0.07 0.04 Asn409 0.45 0.73 0.77 0.09 0.58
Ser410 0.67 2.93 4.99 0.32 1.06 Ser410 0.13 9.67 7.04 0.42 3.18
Met411 2.58 0.60 0.39 0.63 3.00 Met411 4.13 0.43 0.52 0.64 4.86
Phe412 0.23 0.32 0.50 0.00 0.41 Phe412 0.26 0.04 0.19 0.00 0.41
Asp413 1.01 47.00 35.61 0.49 9.88 Asp413 0.51 50.45 37.23 0.24 12.47
Tyr414 1.02 0.83 1.22 0.23 0.86 Tyr414 0.93 0.14 0.07 0.14 1.14
Phe415 0.15 0.39 0.26 0.00 0.28 Phe415 0.11 0.22 0.08 0.00 0.41
a  Gbindsc scbind, Contribution to the total binding free energy,  Gbind, for the four modeled clones. Energies are in kilocalories per mole. Evdwsc , Eelecsc ,  Gelec,desolvsc , and 
Gnp,desolvsc are the van der Waals and electrostatic interaction energies, and the electrostatic and nonpolar desolvation energies calculated for the side chains, respectively.
Table IV. MM-GBSA contributions of CDR1 backbone (bb)a
Evdwbb Eelecbb  Gelec,desolvbb  Gnp,desolvbb  Gbindbb Evdwbb Eelecbb  Gelec,desolvbb  Gnp,desolvbb  Gbindbb
ELGTASY LAU 337–6B7
Tyr407 0.03 0.47 0.57 0.00 0.08 Tyr407 0.03 0.53 0.36 0.00 0.20
Ser408 0.14 1.45 1.44 0.01 0.15 Ser408 0.29 4.67 3.28 0.02 1.09
Asp409 0.51 5.31 3.92 0.07 1.97 Asp409 0.35 1.49 0.98 0.00 0.87
Arg410 0.90 5.53 5.55 0.12 1.00 Arg410 1.02 2.36 4.44 0.17 0.88
Gly411 1.14 5.03 3.65 0.24 2.76 Gly411 0.94 3.77 2.07 0.09 2.74
Ser412 1.51 6.36 5.89 0.13 2.10 Ser412 1.43 5.66 4.38 0.07 2.78
Gln413 0.38 2.61 2.33 0.02 0.12 Gln413 0.37 1.96 1.89 0.00 0.31
Ser414 0.19 0.31 0.52 0.00 0.41 Ser414 0.16 0.06 0.24 0.00 0.14
Phe415 0.05 0.15 0.05 0.00 0.04 Phe415 0.05 0.07 0.04 0.00 0.02
M77–80 A42
Tyr407 0.02 0.40 0.57 0.00 0.15 Tyr407 0.02 0.60 0.99 0.00 0.37
Thr408 0.05 0.26 0.32 0.00 0.01 Thr408 0.06 0.23 0.34 0.00 0.16
Asn409 0.16 0.66 0.93 0.00 0.11 Asn409 0.19 0.98 0.88 0.00 0.29
Ser410 0.71 1.75 0.68 0.06 0.30 Ser410 1.01 0.37 1.13 0.09 0.40
Met411 1.26 1.35 3.19 0.12 0.45 Met411 1.05 1.63 1.65 0.05 1.09
Phe412 0.36 2.64 3.40 0.00 1.12 Phe412 0.27 1.71 1.23 0.00 0.20
Asp413 0.54 1.45 2.99 0.00 2.08 Asp413 0.32 0.49 1.79 0.00 1.62
Tyr414 0.27 0.31 0.89 0.00 1.47 Tyr414 0.18 0.10 0.19 0.00 0.09
Phe415 0.06 0.05 0.13 0.00 0.12 Phe415 0.05 0.12 0.05 0.00 0.02
aGbindbb Contribution to the total binding free energy,  Gbind, for the four modeled clones. Energies are in kilocalories per mole. Evdwbb , Eelecbb ,  Gelec,desolvbb , and  Gnp,desolvbb
are the van der Waals and electrostatic interaction energies, and the electrostatic and nonpolar desolvation energies calculated for the backbone, respectively
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nonamer-specific clones (TCR from clones A42 and M77–80).
Fig. 3 shows the interactions between the glutamic acid at the first
position of the ELA peptide (Glu374) and the TCR CDR1 form-
ing the CDR loop closest to Glu374. This analysis revealed that
similar CDR1 sequences gave similar conformations (Fig. 3B).
For each model, we calculated side chain contributions (Table III)
and backbone contributions (Table IV) to the binding free energy
made by the CDR1 residues, respectively.
For the nonamer-specific clones, the shortest distances between
the heavy atoms of the CDR1 and Glu374 are 3.51 and 3.93 Å,
respectively. No hydrogen bond is formed between CDR1 and
the peptide. The TCR Asp413 is one of the closest residues from
Glu374. The distance between the two corresponding side chain
carboxylates is lower than 5Å. This interaction between two neg-
atively charged residues is strongly unfavorable for the stability of
the complex. We calculated a large unfavorable contribution for
Asp413 in both cases, i.e., 9.88 kcal/M and  12.47 kcal/M for
M77–80 and A42, respectively (Tables III and IV). The electro-
static part, Eelecsc  Gelec,desolvsc , of the binding free energy contri-
bution is highly positive for both models. Such high values of side
chain contributions are rarely observed experimentally. This indi-
cates that this unfavorable interaction probably prevents TCR-p-
MHC binding, or requires a significant and energetically costly
conformational rearrangement, in agreement with the low activity
found in cellular assays. On the contrary, for both decamer-specific
clones, a strong favorable hydrogen bond is formed between the
TCR Ser412 backbone and the peptide Glu374 side chain. The dis-
tances between the heavy atoms are 3.21 and 3.08 Å, respectively
(Fig. 3B), in good agreement with the favorable contributions that
were calculated for the Ser412 backbone, and with the results found
in cellular assays. In both cases, the unfavorable electrostatic de-
solvation, Gelec,desolvbb is more than compensated by the favorable
FIGURE 4. Strategy to distinguish nonamer from decamer specific T cells by staining with two tetramers and V2.1 specific Ab. A, Mixtures of A42
and BC25-R3 clones at different ratios were stained with anti-V2.1 mAb and tetramers prepared with peptides LAGIGILTV (tLA-PE) and ELAGIGILTV
(tELA-allophycocyanin). B, Similar double tetramer stainings were performed on peptide stimulated PBMCs from healthy donors and patients, and on
short-term cultured TIL or TILN cells analyzed directly ex vivo from metastases of melanoma patients. Graphs are DAPInegCD8pos gated.
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electrostatic interactions, Eelecbb . The backbone contributions of
Ser412 are 2.10 kcal/mol and 2.78 kcal/mol for the clones EL-
GTASY and LAU 337–6B7, respectively (Tables III and IV).
Detection of Melan-A nonamer-specific CD8 T cells following in
vitro peptide stimulation of PBMC
The question arose whether the two nonamer-specific clones
represented a rare species of melanoma-specific T cells, or
whether this specificity existed more frequently. To generate a
larger number of nonamer-specific CD8 T cells, we developed
a double tetramer staining strategy by using allophycocyanin-
labeled tetramers bearing the decapeptide ELAGIGILTV
(tELA-allophycocyanin) and PE-labeled tetramers bearing the
nonapeptide LAGIGILTV (tLA-PE), allowing a quantitative
dissection of the TCR repertoire of polyclonal Melan-A-specific
CD8 T cell populations. For validation of this approach, we
stained mixtures of A42 and BC25-R3 clones. Indeed, this al-
lowed to discriminate nonamer from decamer-specific clones.
The two clones were mixed at different ratios, demonstrating
that the double tetramer approach was capable of distinguishing
clone A42 (single tLApos) from clone BC25-R3 (tLApos and
tELApos) in a quantitative manner (Fig. 4A, upper panels). The
addition of V2.1 staining allowed to confirm that double tet-
ramerpos cells were V2.1pos and single tetramer tLApos lym-
phocytes did not express V2.1 (Fig. 4A, lower panels). Sub-
sequently, we used this labeling to analyze the frequency of
Melan-A nona- vs decapeptide-specific cells in polyclonal pop-
ulations. Total PBMC from two healthy donors were stimulated
with Melan-A peptide and cultured for 15 days. As expected,
the majority of Melan-A-specific cells were positive for the
tELA tetramer and these cells were mostly V2.1pos (Fig. 4B,
upper panels, and data not shown), confirming the predomi-
nance of decamer-specific T cells in five donors analyzed. How-
ever, two patients and one healthy donor displayed, after two
rounds of stimulation, a small but distinct tELAneg/tLApos pop-
ulation, at frequencies of 2 and 7% (Fig. 4B, upper panels).
Ex vivo detection of Melan-A nonamer-specific CD8 T cells
In parallel, we also performed double tetramer stainings of TIL and
TILN cells from metastases of four melanoma patients (two TIL
cultured for 2–3 wk, and two TILN cells analyzed directly ex
FIGURE 5. Functional assessment of newly generated nonamer-specific clones. A, Clones generated from PBMCs of patient LAU 269 were labeled with
tetramers tELA, tEAA, tAA, tLA, and tEBV (as negative control) and anti-CD8 mAb, with anti-V2.1 mAb (bold line) or with FITC conjugate alone (filled
histogram). B, Specificity of nonamer-specific clones was measured with T2 target cells (E:T ratio 10:1) in presence of increasing peptide concentrations.
C, Tumor cell lysis was assessed using Me 290 melanoma cells (HLA-A*0201pos/Melan-Apos), and NA8-MEL cells infected with recombinant vaccinia
viruses coding for ELA, EAA, or AA. Similar results were obtained in two independent experiments.
Table V. Detection of nona- and decamer-specific T cellsa
TIL(N) from Patient % tELA/LA % tELA/LA % tELA/LA
LAU 640 83.3 14.7 2
LAU 701 23.7 28.9 47.4
LAU 820 46.6 2.4 51
LAU 1003 50 10 40
aAnalysis of TIL/TILN from four patients. Percentages of Melan-A-specific pop-
ulations positively stained with one or both tetramers (tELA and tLA), by calculating
tLApos plus tELApos cells as 100%.
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vivo), which was possible without in vitro Ag stimulation because
TIL/TILN contain high frequencies of Melan-A-specific T cells
due to spontaneous enrichment in vivo (2, 36, 37). Interestingly,
tELAneg/tLApos populations were found in all four patients, rang-
ing from 0.04 to 4.6% of CD8pos T cells. When we compared this
nonamer-specific subset to the total percentages of Melan-A-spe-
cific CD8 T cells (by calculating tLApos  tELApos cells as
100%.), we observed that tELAneg/tLApos cells could reach up to
half of Melan-A-specific T lymphocytes (Fig. 4B, lower panels,
and Table V). To generate nonamer-specific T cell clones and con-
firm their specificity, tELAneg/tLApos cells were sorted from
TIL(N) or from stimulated PBMC and cloned by limiting dilution.
After expansion, almost all clones obtained from PBMCs con-
firmed to be tELAneg/tLApos and V2.1neg (Fig. 5A and Table VI),
and 8 of 13 clones from TIL(N) were also tELAneg/tLApos (Table
VI). Thus, large numbers of nonamer-specific cells were not only
detected ex vivo, but we were also able to isolate them and gen-
erate nonamer-specific T cell clones demonstrating wide existence
of clones with specificity similar to A42 and M77–80. Functional
analysis confirmed recognition of natural Melan-A nonapeptide as
well as the nonapeptide LA and analog decapeptides (AAA, ALA),
but the nonapeptide AL was still not recognized (Fig. 5B). As
before, we also observed paradoxical recognition of EAA and ELA
decapeptides (Fig. 5B). However, 51Cr-release assays of NA8-
MEL cells infected by vaccinia viruses confirmed that these clones
were truly nonamer-specific, because they killed target cells ex-
pressing AA minigenes, but not EAA or ELA minigenes (Fig. 5C).
Finally, these clones were able to efficiently lyse melanoma cells
without adding exogenous peptides. All together we generated 17
additional nonamer-specific T cell clones with similar properties as
clones A42 and M77–80. To obtain an overview, these 19 clones
were compared with 69 decamer-specific clones with regard to
tetramer binding and expression of V2.1 (30). The data show that
the nonamer-specific clones (all tELAneg) efficiently bound the
tLA tetramer, and were mostly V2neg (Table VII). In contrast,
decamer-specific clones (tELApos) were mostly V2.1pos, while
also staining with tLA tetramers.
Discussion
Among the relatively large number of known tumor associated
Ags which are recognized by human CD8 T cells, Melan-A is one
of the most immunodominant in HLA-A2 melanoma patients (38).
Although the Melan-A27–35 nonapeptide was originally described
as immunodominant antigenic peptide (10), it was subsequently
shown that the Melan-A26–35 decapeptide is the natural peptide
that is recognized most frequently and most efficiently by HLA-
A*0201 and -B*3501-restricted T cells from TIL(N) and PBMC
(5–8). Several reports described that the dominant Melan-A-spe-
cific CD8 T cell response is diverse in terms of TCR usage, and
that most appear to recognize both nona- and decapeptides, and
cross-react with superior functionality with the defined peptide
variant Melan-A26–35(A27L) (6, 7). In contrast to these findings,
we report here that some Melan-A-specific clones do not recognize
the naturally processed decamer. Rather, they display a distinct
specificity to the Melan-A nonamer. We show that a significant
proportion of Melan-A-specific T cells is nonamer but not decamer
specific. Therefore, lack of decamer recognition is due to presence
of glutamic acid (E) in position one of the peptide.
We first compared tetramer staining and functional avidity to
Melan-A natural and modified peptides between majority and minor-
ity clones. We found surprising discrepancies, because minority
clones efficiently recognized decamer labeled target cells but did not
bind to the corresponding tetramers. Using NA8-MEL cells infected
by vaccinia viruses coding for Melan-A minigenes as target cells, we
demonstrated that decamer peptide recognition in cytotoxicity assays
was an experimental artifact, likely due to the uncontrolled presence
of nonapeptides. Thus, our data demonstrate that synthetic peptide
recognition data need to be interpreted with caution. All CD8 T cell
clones successfully recognized the AAA, ALA, and LA analog pep-
tides suggesting that it is the glutamic acid that prevents recognition
by minority, i.e., nonamer-specific clones. A previous study described
a similar phenomenon using HLA-B*4501-restricted clones specific
for the 11-mer (AEEAAGIGILT) from Melan-A. The authors showed
that the presence of threonine at the C terminus abrogated the recog-
nition by a CTL clone, whereas another CTL clone recognized the
peptide irrespective of the presence or absence of the threonine (39).
The structure of the wild-type Melan-A nonamer and decamer/
HLA-A2 complexes are expected to diverge at the N terminus of the
peptides (40). The clones distinguishing the nonamer from the
decamer, as described in this report, appear to interact differentially
with residues near the P1 pocket of the HLA-A2 molecules, which
consists of glutamic acid in the decamer complex, but empty or more
likely water filled moieties in the natural nonamer complex (40, 41),
providing the structural basis for distinguishing the two complexes
(40). Previous studies have emphasized the large diversity but the
highly conserved V2.1 usage of the pre- and postimmune repertoire
of A2/Melan-A-specific CD8 T cells. This was particularly striking in
T cell clones generated with EAA or ELA decapeptides (30, 32, 33).
An earlier study generated clones without peptide (i.e., with the help
Table VII. Summary of tetramer binding and V 2.1 expression by
decamer- and nonamer-specific clones
% tELA % tLA % V2.1
Nonamer-specific clones (n  19) 0 100 5
Decamer-specific clones (n  69) a 100 84b 85
aFrom Dietrich et al. (30) and our unpublished data.
bAs determined in 19 clones.
Table VI. Newly generated LAGIGILTV-specific T cell clonesa
tLA Sorted Clones from tELA tLA V 2.1
Stimulated PBMCs (n  10)
269-1   
269-2   
269-3   
269-4   
269-5   
269-6   
269-7   
269-11   
269-9   
269-10   
TIL(N) (n  13)
701-1   
701-2   
701-3   
701-11   
701-30   
701-41   
701-38   
820-4   
820-9   
820-1   
820-2   
820-3   
820-10   
aThe clones were derived from PBMCs and TIL(N) as indicated, and demon-
strated systematic binding to tLA tetramers and infrequent expression of V2.
7643The Journal of Immunology
of mixed lymphocyte tumor cell cultures) and found that six of nine
clones expressed V2 (34), suggesting that naturally presented
Melan-A peptides (likely nona- plus decapeptides) may already in-
duce some V2 bias. Our structural modeling data show that V2.1
seems highly favorable for the canonical interaction between TCR
and ELA/HLA-A2 complex (Fig. 3B and Tables III and IV), while
CDR1 of nonamer-specific clones exhibit an unfavorable interaction
between Glu374 of the peptide and Asp413 of TCR. This suggests that
the glutamic acid at the N terminus of decapeptides may contribute to
selection of TCRs bearing V2.1. One may speculate that already in
the thymus, V2.1-expressing TCRs might preferentially interact
with glutamic acid leading to more frequent selection of V2.1-pos-
itive T cells. The described extraordinary high frequency of naive
Melan-A-specific cells which are frequently V2.1 and decamer spe-
cific (1, 30, 42–44) may however not be entirely explained by the
existence of a single hydrogen bond between CDR1 and glutamic
acid of the decapeptide, as several human TCR Vmight have similar
favorable interactions. More extended structural analyses are neces-
sary to test the hypothesis whether the overall sequences and struc-
tures of V2-negative TCRs may be inappropriate to interact with the
ELA/HLA-A2 complex. Finally, absence of glutamic acid in the non-
apeptide seems not to confer preferential recognition by V2.1-ex-
pressing TCRs, although V2.1 may occasionally be expressed by
nonamer-specific T cells (Table VI and VII).
According to TCR function/structure relationship analysis, and to
recent data from crystallized HLA-A*0201 peptide complexes (40),
recognition of the various peptides studied here by Melan-A-specific
T cell clones appears to be based on a the following peptide confor-
mation: The second amino acid of the decamers is anchored in P2
pocket, and the C-terminal valine in P9 pocket of the peptide binding
groove of HLA-A*0201. In this conformation the decamer forms a
kink, i.e., it bends out of the groove toward the TCR (40). By contrast,
the conformation of the natural nonamer is not known. A recent study
with crystallized nonamer AL/HLA-A*0201 complexes revealed that
the AL peptide lies in a flat conformation in the peptide binding
groove (40). We used this peptide systematically in our peptide titra-
tion assay, and found that the majority of Melan-A-specific CD8 T
cells do not recognized this AL nonamer (Figs. 2A and 5B and data
not shown), suggesting that the AA peptide (i.e., the wild-type
nonamer) is recognized when presented in a kink conformation,
which is generated when the first alanine lies in pocket P2. The cur-
rent available HLA-A2/Melan-A-specific clones, no matter whether
they are nonamer or decamer-specific, may recognize the kink con-
formation. Thus, based on the available data, the kink but not the flat
conformation of Melan-A peptides appears to be recognized by mel-
anoma-specific T cells. However, future studies must focus on the
question whether Melan-A-specific T cells with different fine speci-
ficities may exist that indeed can recognize melanoma cells based on
the AA peptide presented in a flat conformation, i.e., with the second
alanine in pocket P2.
We found high percentages of nonamer-specific CD8 T cells in
TIL(N) from unvaccinated melanoma patients, demonstrating the fre-
quent presence of such T cells in vivo (Fig. 4B and Table V). Spec-
ificity was confirmed by the analysis of 13 Melan-A-specific CD8 T
cell clones derived from TIL(N) and generated in absence of synthetic
peptide. These results indicate that nonamer-specific CD8 T cells are
efficiently primed and expanded in vivo in melanoma patients. Thus,
not only decamer but also nonamer-specific T cells are substantially
enriched in melanoma lesions. This is remarkable, given the weak
antigenicity of the nonamer, caused by the weak binding to HLA-
A*0201. It is therefore possible that nonamer-specific TCRs are of
higher affinity allowing to compensate for low p-MHC stability.
Several reasons may explain why most laboratories generate
decamer but not nonamer-specific T cell clones. Most researchers use
the Melan-A decamer peptides, because they are more strongly anti-
genic and thus lead to stronger proliferation than the nonapeptides.
The enhanced p-MHC stability is also the reason why tetramers are
mostly prepared with decamers. Consequently, T cell cloning is often
done through sorting with decamer-tetramers, and they are subse-
quently also used to screen for positive and negative clones.
Immunotherapy of melanoma patients more often applies Melan-A
decapeptides than nonapeptides (45), again because the former are
more strongly antigenic. In deed, previous studies with the nonapep-
tide AAGIGILTV induced only weak immune responses (46). How-
ever, novel vaccine adjuvants substantially increase the likelihood of
strong human T cell responses even with weakly antigenic peptides
(Ref. 47 and D. E. Speiser et al., submitted for publication). Based on
our present data, the use of Melan-A nonapeptides for vaccination
should be encouraged (48), to elicit nonamer-specific T cell responses
in vivo and evaluate their protective potential.
Together, our data reveal a new face of HLA-A*0201/Melan-
A-specific CD8 T cells, revealing a population of T cells exclu-
sively specific for the nonapeptide, representing a significant pro-
portion of Melan-A-specific T cells. The specificity difference
between nonamer and decamer-specific T cells is more pro-
nounced than previously thought. Although some cells are cross-
reactive, this has been largely overestimated in the past, based on
functional experiments with peptides that do not allow precise dis-
tinction between recognition of nonamers and decamers. Tetram-
ers are much better suited for this distinction, a remarkable finding
given the usually high level of cross-specific binding by tetramers.
We conclude that the two types of cells are specific for two dif-
ferent epitopes, rather than just cross-reactive.
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